Homocysteine is associated with the progression of non-culprit coronary lesions in elderly acute coronary syndrome patients after percutaneous coronary intervention

被引:10
作者
Han, Tian-Wen [1 ]
Zhou, Shan-Shan [1 ]
Li, Jian-Tao [1 ]
Tian, Feng [1 ]
Mu, Yang [1 ]
Jing, Jing [1 ]
Han, Yun-Feng [1 ]
Chen, Yun-Dai [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Fuxing Rd 28, Beijing 100853, Peoples R China
关键词
Coronary angiography; Elderly patients; Homocysteine; Non-culprit coronary lesion; Percutaneous coronary intervention; PLASMA HOMOCYSTEINE; VASCULAR-DISEASE; RISK-FACTOR; METHYLENETETRAHYDROFOLATE REDUCTASE; MYOCARDIAL-INFARCTION; OXIDATIVE STRESS; ARTERY-DISEASE; STABLE ANGINA; RESTENOSIS; HYPERHOMOCYSTEINEMIA;
D O I
10.11909/j.issn.1671-5411.2016.04.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The influence of homocysteine (Hcy) on the migration and proliferation of vascular smooth muscle cells has been well established. However, the impact of Hcy levels on the progression of non-culprit coronary lesions (NCCLs) is controversial. This study aims to evaluate whether the plasma level of Hcy is related to the progression of NCCLs after percutaneous coronary stent implantation in elderly patients with acute coronary syndrome (ACS). Methods A total of 223 elderly patients (>= 65 years old) with ACS undergoing stent implantation and follow-up coronary angiography were enrolled. Laboratory determination comprised of blood sample evaluation for Hcy was carried out before baseline coronary intervention. The patients were classified into two groups according to the blood Hcy tertiles (>= 15 mmol/L or < 15 mmol/L). Patients were followed up for 12.2 months. NCCL progression was assessed by three-dimensional quantitative coronary angiography. Results A significantly higher ratio of NCCL progression was observed in the group with baseline Hcy concentrations above 15 mmol/L compared to the group with concentrations below 15 mmol/L (41/127, 32.3% vs. 14/96, 14.6%, P = 0.002). Multivariate Cox regression analysis showed that Hcy and diabetes mellitus were independent risk factors for NCCL progression. The crude hazard ratio (HR) of NCCL progression for Hcy level was 1.056 (95% CI: 1.01-1.104, P = 0.015). The adjusted HR of NCCL progression for Hcy level was 1.024 (95% CI: 1.007-1.042, P = 0.007). The adjusted HR of NCCL progression for diabetes mellitus was 1.992 (95% CI: 1.15-3.44, P = 0.013). Conclusions Hcy is an independent risk factor for NCCL progression after 12 months of follow-up in elderly patients with ACS who has undergone percutaneous coronary stenting.
引用
收藏
页码:299 / 305
页数:7
相关论文
共 42 条
  • [1] SERUM TOTAL HOMOCYSTEINE AND CORONARY HEART-DISEASE
    ARNESEN, E
    REFSUM, H
    BONAA, KH
    UELAND, PM
    FORDE, OH
    NORDREHAUG, JE
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (04) : 704 - 709
  • [2] A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES
    BOUSHEY, CJ
    BERESFORD, SAA
    OMENN, GS
    MOTULSKY, AG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13): : 1049 - 1057
  • [3] Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014
    Byrne, Robert A.
    Joner, Michael
    Kastrati, Adnan
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (47) : 3320 - +
  • [4] Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease
    Camici, Giovanni G.
    Savarese, Gianluigi
    Akhmedov, Alexander
    Luescher, Thomas F.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (48) : 3392 - U109
  • [5] Hyperhomocysteinemia and venous thromboembolism
    Cattaneo, Marco
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (07) : 716 - 723
  • [6] Chen Zhe, 2005, Chinese Medical Sciences Journal, V20, P63
  • [7] Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis
    Clarke, R
    Collins, R
    Lewington, S
    Donald, A
    Alfthan, G
    Tuomilehto, J
    Arnesen, E
    Bonaa, K
    Blacher, J
    Boers, GHJ
    Bostom, A
    Bots, ML
    Grobee, DE
    Brattström, L
    Breteler, MMB
    Hofman, A
    Chambers, JC
    Kooner, JS
    Coull, BM
    Evans, RW
    Kuller, LH
    Evers, S
    Folsom, AR
    Freyburger, G
    Parrot, F
    Genst, J
    Dalery, K
    Graham, IM
    Daly, L
    Hoogeveen, EK
    Kostense, PJ
    Stehouwer, CDA
    Hopknis, PN
    Jacques, P
    Selhub, J
    Luft, FC
    Jungers, P
    Lindgren, A
    Lolin, YI
    Loehrer, F
    Fowler, B
    Mansoor, MA
    Malinow, MR
    Ducimetiere, P
    Nygard, O
    Refsum, H
    Vollset, SE
    Ueland, PM
    Omenn, GS
    Beresford, SAA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16): : 2015 - 2022
  • [8] Homocysteine, coagulation, platelet function, and thrombosis
    Coppola, A
    Davi, G
    De Stefano, V
    Mancini, FP
    Cerbone, AM
    Di Minno, G
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (03) : 243 - 254
  • [9] Beyond restenosis - Five-year clinical outcomes from second-generation coronary stent trials
    Cutlip, DE
    Chhabra, AG
    Baim, DS
    Chauhan, MS
    Marulkar, S
    Massaro, J
    Bakhai, A
    Cohen, DJ
    Kuntz, RE
    Ho, KKL
    [J]. CIRCULATION, 2004, 110 (10) : 1226 - 1230
  • [10] Homocysteine and its effects on in-stent restenosis
    De Luca, G
    Suryapranata, H
    Gregorio, G
    Lange, H
    Chiariello, M
    [J]. CIRCULATION, 2005, 112 (19) : E307 - E311